



PONTIFÍCIA UNIVERSIDADE CATÓLICA DO PARANÁ
ESCOLA DE SAÚDE E BIOCÊNCIAS
PROGRAMA DE MESTRADO EM ODONTOLOGIA
ÁREA DE CONCENTRAÇÃO ENDODONTIA

ANDRÉIA BONATO PAROLIN

EXPRESSÃO DE MATRIZ DE METALOPROTEINASE-2
CORRELACIONADA A BACTÉRIAS GRAM-NEGATIVAS
EM LESÕES PERIAPICAIS SINTOMÁTICAS E
ASSINTOMÁTICAS

Curitiba
2014

ANDRÉIA BONATO PAROLIN

**EXPRESSÃO DE MATRIZ DE METALOPROTEINASE-2
CORRELACIONADA A BACTÉRIAS GRAM-NEGATIVAS
EM LESÕES PERIAPICAIS SINTOMÁTICAS E
ASSINTOMÁTICAS**

Dissertação apresentada ao Programa de Pós-Graduação em odontologia da Pontifícia Universidade Católica do Paraná, como parte dos requisitos para obtenção do título de Mestre em odontologia, Área de Concentração em Endodontia.

Orientador : Everdan Carneiro

Curitiba

2014

Dados da Catalogação na Publicação
Pontifícia Universidade Católica do Paraná
Sistema Integrado de Bibliotecas – SIBI/PUCPR
Biblioteca Central

P257e
2014 Parolin, Andréia Bonato
Expressão de matriz de metaloproteinase-2 correlacionada a bactérias gram-negativas em lesões periapicais sintomáticas e assintomáticas / Andréia Bonato Parolin ; orientador, Everdan Carneiro. – 2014.
53 f. : il. ; 30 cm

Dissertação (mestrado) – Pontifícia Universidade Católica do Paraná, Curitiba, 2014
Inclui bibliografias
Texto em português e inglês

1. Odontologia. 2. Endodontia. 3. Periodontite periapical. 4. Doenças periapicais. 5. Bactérias gram-negativas. I. Carneiro, Everdan. II. Pontifícia Universidade Católica do Paraná. Programa de Pós-Graduação em Odontologia. III. Título.

CDD 20. ed. – 617.6

TERMO DE APROVAÇÃO

ANDREIA BONATO PAROLIN

EXPRESSÃO DE MATRIZ DE METALOPROTEINASE-2 CORRELACIONADA A BACTÉRIAS GRAM-NEGATIVAS EM LESÕES PERIAPICAIS SINTOMÁTICAS E ASSINTOMÁTICAS


Dissertação apresentada ao Programa de Pós-Graduação em Odontologia da Pontifícia Universidade Católica do Paraná, como parte dos requisitos parciais para a obtenção do Título de **Mestre em Odontologia**, Área de Concentração em **Endodontia**.



Orientador(a): Prof. Dr. Everdan Carneiro
Programa de Pós-Graduação em Odontologia, PUCPR



Profª Drª Aline Cristina Batista Rodrigues Johann
Programa de Pós-Graduação em Odontologia, PUCPR



Prof. Dr. Rodrigo Cardoso de Oliveira
Programa de Pós-Graduação em Ciências Odontológicas Aplicadas,
FOB-USP

Curitiba, 31 de outubro de 2014.

AGRADECIMENTOS

Em primeiro lugar, quero agradecer ao meu eterno amigo e companheiro, meu marido Ivan Parolin Filho e aos meus filhos Matheus e Gabriel, pelo apoio, dedicação, auxílio e compreensão nestes momento de árduas pesquisas.

Pela paciência, orientação implacável e a amizade do meu Orientador Everdan Carneiro, que me levou a trilhar caminhos antes inimagináveis no campo da Odontologia, redundando neste trabalho que, ao mesmo tempo, já provoca novos desafios.

Aos Professores Natanael Ribeiro Mattos, Liliane Roskamp, Vania Portela Ditzel Westphalen, Ulisses Xavier da Silva Neto, Luiz Fernando Fariniuk e Aline Cristina Batista Rodrigues Johann, que brilharam com seus ensinamentos como uma luz ao final do túnel.

A todos, além do meu profundo agradecimento, meu reconhecimento, minha gratidão e minhas preces para que Deus continue abençoando suas vidas e suas mentes.

SUMÁRIO

ARTIGO EM PORTUGUÊS	1
Resumo	2
Introdução	3
Materiais e Métodos	4
Seleção dos Pacientes	4
Imunohistoquímica	4
Coloração Gram	5
Análise Quantitativa de Imagens.....	5
Análise Estatística	6
Resultados	6
Discussão	7
Referências	9
ARTIGO EM INGLÊS.....	11
Abstract.....	12
Introduction	13
Material and Methods.....	14
Patient Selection	14
Immunohistochemistry	14
Gram Stain	15
Quantitative Image Analysis.....	15
Statistical Analysis.....	16
Results	16
Discussion	17
References	19
ANEXOS	21
Parecer do Comitê de Ética.....	22
Análise Estatística.....	26
Resultados	27
GRAM.....	30
MMP	33
Resultados Finais.....	37
Normas para Publicação	38

LISTA DE FIGURAS

Figura 1 – Quantidade de bactérias Gram- Negativa.....	6
Figura 2 – Expressão de MMP-2.....	6
Figura 3 - A: Grupo Assintomático – Área com células inflamatórias imunopositivas para MMP-2, na seta sugestivo de macrófago. B: Grupo Sintomático - Área com células inflamatórias imunopositivas para MMP-2, na seta sugestivo de neutrófilo. C: Grupo Assintomático – Área com células imunopositivas para MMP-2. D: Grupo Assintomático – Área com células imunopositivas para MMP	7

1

2

4

6

7

8

9

10

11

12

14

15

1 **Resumo**

2 Introdução: Determinar se a hipótese que a expressão de matriz
3 metaloproteinase-2 (MMP-2) é significativamente elevada em pacientes com
4 periodontite apical sintomática e correlacionar com a quantidade detectada de
5 bactérias gram-negativas. Métodos: Vinte pacientes com lesões periapicais foram
6 divididos em 2 grupos: o grupo sintomático (ASSIN) incluindo 10 pacientes
7 expressando lesão periapical e dor, e o grupo assintomático (SIN), incluindo 10
8 pacientes sem expressar dor. Todos os dentes foram retratados endodonticamente,
9 pelo menos, dois anos antes da cirurgia periapical. As lesões periapicais foram
10 coletadas e serialmente seccionadas em cortes de 4µm. Pelo menos duas secções
11 foram processadas para exame microscópico com hematoxilina-eosina. Outras
12 secções foram processadas para imunohistoquímica. Para a MMP-2, a área
13 selecionada com células imunopositivas foi medida, e a percentagem de MMP-2, em
14 relação a área total do campo microscópico foi calculada. Para as bactérias gram-
15 negativas, o número de bactéria que apresentavam a cor rosa vermelhada foi
16 contado por campo microscópico. O teste T-Student foi utilizado para comparar os
17 grupos SIN e ASSIN. O Coeficiente de correlação de Pearson foi utilizado para
18 determinar uma correlação significativa entre o número de bactérias gram-negativas
19 e os níveis de MMP-2. O nível de significância foi estabelecida em $p < 0,05$.
20 Resultados: Pelo percentual de área do MMP-2, o grupo ASSIN mostrou uma média
21 estatisticamente maior do que o grupo SIN ($p = 0,027$). O grupo SIN mostrou um
22 aumento estatisticamente significativo no número de células gram-negativas ($p =$
23 0,003) quando comparado ao ASSIN. Não houve correlação positiva
24 estatisticamente significativa entre o número de bactéria gram-negativas e a
25 porcentagem de área de MMP-2 ($p = 0,187$). Conclusão: Existe fraca evidência de
26 um papel significativo de bactérias gram-negativas e MMP-2 em lesões periapicais
27 sintomáticas.

28
29 Palavras-chave: bactérias gram-negativas; matriz metaloproteinase-2; lesões
30 periapicais; sintomático.

1 Introdução

2 A periodontite apical é uma doença inflamatória dos tecidos peri-radiculares
3 causadas por infecção microbiana persistente dentro do sistema de canal radicular
4 do dente afetado.¹ Pode ter uma fase aguda ou crônica. A inflamação aguda
5 (sintomática) é uma resposta exsudativa, enquanto que a inflamação crônica é mais
6 proliferativa (assintomática).²

7 As metaloproteinases da matriz (MMPs) são uma família de endopeptidases
8 metais-dependentes que representam a maioria das classes de enzimas
9 responsáveis pela degradação dos componentes da matriz extracelular (ECM).³ A
10 MMP-1 tem sido relacionada como chave na iniciação da fase de reabsorção óssea
11 na periodontite apical.⁴ Além de MMP-2, MMP-3, MMP-8, MMP-9 e MMP-13 que
12 foram descritas em lesões periapicais^{5,6,7,8,9} e desempenham um papel de suma
13 importância durante o desenvolvimento de patologia periapical.^{8,10} Entretanto, foi
14 sugerido recentemente que há boas evidências para suspeitar de um papel
15 significativo de bactérias gram-negativas e MMP-9 em lesões periapicais
16 sintomáticas.¹¹ A MMP-2 também conhecida como gelatinase A, é uma proteína
17 ligada à membrana que é de suma importância para o *turnover* da matriz
18 extracelular, preferencialmente clivar colágeno tipo IV, V, VII e XI e gelatina.¹² A
19 imunomarcagem para a MMP-2 na lesão periapical foi expressa, principalmente pelos
20 fibroblastos, células endoteliais, monócitos / macrófagos e osteoblastos.⁵ Durante a
21 fase de desenvolvimento da lesão, a MMP-2 e MMP-9 foram descritas, por
22 desempenhar um papel crítico.¹⁰ Por outro lado, tem sido relatado que os níveis de
23 MMP-9 aumentaram, enquanto que os níveis de MMP-2 diminuíram em comparação
24 com polpas inflamadas e polpas saudáveis.¹³ Além disso, foram também relatadas
25 diferentes níveis entre MMP-2 e MMP-9 em abscessos periapicais agudos e
26 crônicos.¹⁴

27 O objetivo deste estudo foi testar a hipótese de que a expressão da MMP-2 é
28 significativamente elevada em pacientes com periodontite apical sintomática e
29 correlacionar com a quantidade detectada de bactérias gram-negativas.

1 **Materiais e Métodos**

2 Seleção dos Pacientes

3 Vinte pacientes com lesões periapicais foram selecionados para este estudo.
4 O diagnóstico de periodontite apical foi baseado principalmente no exame
5 radiográfico, o que demonstra a perda óssea clara e desaparecimento do espaço do
6 ligamento periodontal na região periapical. Todas as amostras de tecido (n = 20)
7 foram da região anterior superior envolvendo apenas um dente de cada paciente. A
8 idade dos pacientes variou de 19 a 41 anos. Apenas pacientes livres de medicação
9 foram incluídos na pesquisa. Todos os procedimentos foram realizados após a
10 obtenção da aprovação do comitê de Ética da Pontifícia Universidade Católica do
11 Paraná, Brasil, Número Parecer: 459.509, e os pacientes assinaram um formulário
12 com o termo de consentimento. Os pacientes foram divididos em dois grupos: o
13 grupo sintomático (SIN), que incluía 10 pacientes com queixa de dor severa e
14 constante, antes da cirurgia endodôntica, e o grupo assintomático (ASSIN), que
15 incluía 10 pacientes sem dor ou sintomas. Todos os dentes foram retratados
16 endodonticamente em um período de até dois anos antes da cirurgia periapical. No
17 grupo assintomático, a imagem das lesões periapicais tinha aumentado quando
18 comparado com a radiografia inicial do retratamento endodontico. No grupo SIN a
19 periodontite aguda estava presente e poderia sugerir insucesso no retratamento. A
20 cirurgia periapical foi realizada em todos os dentes e o tecido periapical foi coletado
21 e imediatamente imersos em formalina neutra 10% tamponada durante 24 horas e,
22 em seguida, cortados em secções de 4µm. Duas secções foram processadas para
23 exame imuno-histoquímico. Outras duas secções foram processadas para exame
24 histológico utilizando coloração de gram-negativo.

25 Imunohistoquímica

26 As secções de tecido em lâmina de vidro foram desparafinadas por
27 aquecimento a 60 ° C, seguido de passagens através de xilol e graduação alcoólica
28 e finalmente, a água. A recuperação antígenoica foi efetuada por fervura das lâminas
29 em solução tampão de citrato 10MN, pH 6,0 durante 10 minutos, seguido de

esfriamento no mesmo tampão durante 30 min. A peroxidase endógena foi bloqueada por incubação com 0,3% de H₂O₂ em metanol durante 15 min. Logo em seguida, os cortes foram incubados em soro normal 3%, diluído em água destilada à temperatura ambiente durante 20 min., e foram incubadas sequencialmente com MMP-2 (37150, ABCAM, EUA). Após o período de incubação, (overnight), as secções foram lavadas com PBS e incubadas com HRP WITH ADVANCE™ Enzima (DAKO®, EUA). As secções foram lavadas com TBS tris pH 7,3. Os cortes foram tratados com substrato 3, 3'-diaminobenzidina tetrahidrocloreto (DAB) (SIGMA ALDRICH, D5637, ST. LOUIS, MO, EUA) para um máximo de 5 minutos à temperatura ambiente. O DAB foi enxaguado, posteriormente, o contraste com hematoxilina Mayer e coberturas deslizantes foram realizadas conforme as etapas finais antes das lâminas serem analisadas em microscópio ótico.

Coloração Gram

Após desparanifização e reidratação, os cortes foram corados em violeta cristal 1% por 15 minutos. Os cortes foram então inundados por 30 segundos com Lugol iodo por acetona por 2 segundos. As secções foram lavadas com água imediatamente após e contrastadas com carbol-fucsina durante 20 segundos e, em seguida, lavado com água e secas com papel absorvente. Bactérias gram-negativas foram coradas com pigmento rosa-vermelho.¹¹

Análise Quantitativa de Imagens

Para cada secção positiva, dez campos microscópicos mostrando a maior imuno-positividade foram selecionados e fotomicrografadas com uma ampliação de 400X (BX50, Olympus, Tóquio, Japão). Todas as etapas de análise imunohistoquímica e gram foram realizadas utilizando um software de análise de imagem (Dino-eye, Anmo Electronics Corporation, Taiwan). Para MMP-2, a fração de área das células positivas foi medida, e a percentagem de MMP-2 imunopositiva em relação à área total do campo do microscópio foi calculada. Para as células gram-negativas coradas, o número de células que apresentam a cor rosa-vermelho foi contado por campo microscópico.¹¹

1 Análise Estatística

2 Os dados foram analisados por meio de testes de normalidade Kolmogorov-
3 Smirnov e Shapiro-Wilk. Os testes mostraram que os dados apresentaram
4 distribuição normal (paramétrico). Foi utilizado o teste T Student para comparar os
5 grupos SIN e ASSIN. O Coeficiente de correlação de Pearson foi utilizado para
6 determinar uma correlação significativa entre o número de células e o nível de MMP-
7 2. O nível de significância foi fixado em $p \leq .05$. A análise estatística foi realizada.

8 Resultados

9 Para a MMP-2, a percentagem de área imunopositiva, o grupo ASSIN
10 apresentou uma percentagem significativamente maior do que a área do grupo SIN
11 ($p = 0,027$, Figura 1). Para as bactérias gram-negativas, o grupo SIN mostrou um
12 número significativamente maior do que a média do grupo assintomático. ($p = 0,003$,
13 Figura 2).




Figura 1 – Quantidade de bactérias Gram-Negativa





Figura 2 – Expressão de MMP-2

15 A expressão imunohistoquímica de MMP-2 foi expressa, principalmente por
16 macrófagos, células do tipo fibroblasto, células epiteliais, células endoteliais (Figura
17 3). Não houve uma correlação positiva estatisticamente significante entre o número
18 de bactérias gram-negativas e da porcentagem de área de MMP-2 ($p = 0,187$).
19 20
21



2 Figura 3 - A: Grupo Assintomático – Área com células inflamatórias imunopositivas para MMP-2, na
3 seta sugestivo de macrófago. B: Grupo Sintomático - Área com células inflamatórias imunopositivas
4 para MMP-2, na seta sugestivo de neutrófilo. C: Grupo Assintomático – Área com células
5 imunopositivas para MMP-2. D: Grupo Assintomático – Área com células imunopositivas para MMP

6 Discussão

7 As MMPs têm sido identificadas tanto em inflamações pulpareas quanto
8 periapicais.^{13,6} As MMPs podem também estar envolvidas em processos fisiológicos
9 quanto patológicos, fenômenos que ocorrem no meio bucal.¹⁵

1 As MMPs desenvolvem um importante papel na destruição do tecido pulpar e
2 tem sido proposto que a MMP-1, MMP-8, MMP-9 e MMP-13 juntas estão envolvidas
3 em casos de expansões de lesões císticas.^{7,8,16}

4 Estudos anteriores já mostraram imunomarcção para MMP-2.^{5,10} No
5 presente estudo, marcações positivas para MMP-2 foram detectadas em células
6 semelhantes a macrófagos, células semelhantes a fibroblastos, células epiteliais e
7 endoteliais.

8 O aumento no nível de MMP-2 foi observado em cultura de células de polpa e
9 ligamento periodontal humanos, quando estas foram expostas a *porphyromonas*
10 *endodontalis and gingivalis*, sendo comumente estas bactérias associadas a
11 abscessos periapicais agudos. Por outro lado, a MMP-2 pode ser detectada em
12 amostras de abscessos periapicais agudos a níveis menos expressivos quando
13 comparados com a MMP-9.¹⁴

14 Diferentes padrões na expressão entre as gelatinases MMP-2 e MMP-9 tem
15 sido descritos na literatura. Estudos em cultura de células de polpa humana
16 demonstraram produzir primeiramente MMP-2 e MMP-9, entretanto, quando a IL-1
17 foi introduzida no meio, as células tiveram os níveis de MMP-2 elevados, contudo IL-
18 1 não afetou os níveis de MMP-9 no oitavo dia do período de cultura.¹⁷

19 O achado mais interessante no presente estudo foi o padrão de expressão de
20 MMP-2, o qual foi o oposto de um estudo usando a mesma metodologia, mas
21 estudando a MMP-9.¹¹ MMP-2 e MMP-9 tem sido descrito por representar um
22 importante papel durante o desenvolvimento da lesão periapical.¹⁰ Por outro lado,
23 quando a lesão periapical é estabelecida, as gelatinas podem apresentar um
24 diferente comportamento. Nesse estudo, a marcação de MMP-2 no grupo
25 assintomático foi mais alta quando comparado com o grupo sintomático, contudo,
26 isto pode sugerir um diferente papel quando comparado com a MMP-9 em
27 periodontite aguda.

28 Tem sido sugerido que algumas bactérias gram negativas estão envolvida em
29 lesões periapicais sintomáticas.¹⁸ Contudo no presente estudo não houve correlação
30 entre bactérias gram negativas e o aumento da atividade de MMP-2 em lesões
31 periapicais sintomáticas. Isto pode sugerir um equilíbrio entre as gelatinases,
32 provavelmente existem diferentes padrões, quando a MMP-9 aumenta sua
33 expressão, a MMP-2 recebe sinais para diminuir.

Para bactérias gram negativas, o grupo SIN apresentou estatisticamente maior número do que o grupo ASSIM. Baseado nesses resultados pode-se sugerir que as bactérias gram negativas podem não desempenhar um importante papel na atividade de MMP-2 quando a lesão está assintomática. Com base nos resultados, pode-se concluir que as bactérias gram-negativas não podem desempenhar um papel importante na atividade de MMP-2, quando a lesão periapical é sintomática.

Referências

1. Kakehashi S, Stanley HR, Fitzgerald RJ. The effects of surgical exposures of dental pulps in germ-free and conventional laboratory rats. *Oral surg Oral Med Oral Pathol Oral Radiol Endod* 1965;20:340-9.

2. Marton IJ, Kiss C. Protective and destructive immune reactions in apical periodontitis. *Oral Microbiol Immunol* 2000;15:139-50.

3. Birkedal-Hansen H, Moore WG, Bodden MK et al. Matrix metalloproteinases: a review. *Crit Rev Oral Biol Med* 1993;4:197-250.

4. Lin SK, Kok SH, Kuo MYP, et al. Sequential expression of MMP-1, TIMP-1, IL-6 and COX-2 genes in induced periapical lesions in rats. *Eur J Oral Sci* 2002;110:246-53.

5. Shin SJ, Lee J, Baek SH, Lin SS. Tissue levels of matrix metalloproteinase in pulps and periapical lesions. *J Endod* 2002;28:313-5.

6. Wahlgren J, Salo T, Teronen O, Luoto H, Sorsa T, Tjäderhane L. Matrix metalloproteinase-8 (MMP-8) in pulpal and periapical inflammation and periapical root-canal exsudates. *Int Endod J* 2002;35:897-904.

7. Leonardi R, Caltabiano R, Loreto C. Collagenase-3 (MMP-13) is expressed in periapical lesions: an immunohistochemical study. *Int Endod J* 2005;38:297-301.

8. Carneiro E, Menezes R, Garlet GP, et al. Expression analysis of matrix metalloproteinase-9 in epithelialized and non-epithelialized apical periodontitis lesions. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2009;107:127-32.

9. Paula-Silva FWG, D'Silva NJ, Silva LAB, Kapila YL. High matrix metalloproteinase activity is a hallmark of periapical granulomas. *J Endod* 2009;35:723-6.

10. Corotti MV, Zambuzzi WF, Paiva KB, et al. Immunolocalization of matrix metalloproteinases-2 and -9 during apical periodontitis development. Arch Oral Biol 2009;54:764-71.
11. Ahmed GM, El-Baz AA, Hashem AAR, Shalaan AK. Expression levels of matrix metalloproteinase-9 and gram-negative bacteria in symptomatic and asymptomatic periapical lesions. J Endod 2013 Apr;39(4):444-8.doi: 10.1016/j.joen.2012.11.009. Epub 2013 Jan 16.
12. Price SJ, Greaves DR, Watkins H. Identification of novel functional genetic variants in the human matrix metalloproteinase-2 gene:role of Sp1 in allele-specific transcriptional regulation. J Biol chem 2001;27:7549-58.
13. Gusman H, Santana RB, Zehnder M. Matrix metalloproteinase levels and gelatinolytic activity in clinically healthy and inflamed human dental pulps. Eur J Oral Sci 2002;110:353-7.
14. Buzoglu HD, Unal H, Ulger C, et al. The zymographic evaluation of gelatinase (MMP-2 and -9) levels in acute and chronic periapical abscesses. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;108:e-121-26.
15. Hannas AR, Pereira JC, Granjeiro JM, Tjaderhane L. The role of matrix metalloproteinases in the oral environment. Acta Odont Scand 2007;65:1-13.
16. Teronen O, Salo T, Kontinen YT, et al. Identification and characterization of gelatinase/type IV collagenase in jaw cysts. J Oral Pathol Med 1995;24:78-84.
17. Chang YC, Lai CC, Yang SF, Chan Y, Hsieh YS. Stimulation of matrix metalloproteinases by black-pigmented bacteroides in human pulp and periodontal ligament cell cultures. J Endod 2002;28:90-3.
18. Siqueira JF. Update on endodontic microbiology: candidate pathogens and patterns of colonization. Endod Pract today 2009;2:7-20.

1 **ARTIGO EM INGLÊS**

2 Expression levels of matrix metalloproteinase-2 and gram-negative bacteria in
3 symptomatic and asymptomatic periapical lesions
4

5 Andreia Bonato Parolin^a

6 Vania Portela Ditzel Westphalen^a

7 Ulisses Xavier da Silva Neto^b

8 Luiz Fernando Fariniuk^b

9 Aline Cristina Batista Rodrigues Johann^c

10 Everdan Carneiro^b

11

12

13 a. Mestranda em Endodontia PUCPR.

14 b. Professor do Mestrado em Odontologia, área de concentração Endodontia.

15 c. Professor do Mestrado em Odontologia, área de concentração Estomatologia.

16

17

Abstract

Introduction: To determine whether the hypothesis that the expression of matrix metalloproteinase (MMP-2) is significantly elevated in patients with symptomatic apical periodontitis and to correlate this with the detected amount of gram-negative bacteria. Methods: Twenty patients with periapical lesions were divided into 2 groups: ten symptomatic (SYM) group included 10 patients expressing pain with periapical lesion, and the asymptomatic (ASYM) group included 10 patients expressing no pain. All teeth had been endodontically retreated at least two year before the periapical surgery. The periapical lesions were collected. Periapical lesions were serially cut into 4µm sections. At least 2 sections were processed for histological examination using hematoxylin-eosin stain. Other sections were processed for immunohistochemical examination. For MMP-2, the area fraction of the positive cells was measured, and the percentage of the MMP-2 imunopositive area to the total area of the microscopic field was calculated. For gram-negative stain cells, the number of cells showing the pink-red color was counted per microscopic field. The Student's test was used to compare SYM and ASYM groups. The Pearson correlation coefficient was used to determine a significant correlation between the number of cells and MMP-2 levels. The significance was set at $p < .05$. **Results:** For MMP-2 area percent the ASYM group showed statistically significant higher mean than SYM group ($p = .027$).

The SYM group showed a statistically significant higher mean number of gram-negative cells ($p = .003$). There was no statistically significant positive correlation between the number of gram-negative cells and the MMP-2 area percent ($p = .187$). Conclusion: There is weak evidence to suspect a significant role of gram-negative bacteria and MMP-2 in symptomatic periapical lesions.

Keys words: gram-negative bacteria; matrix metalloproteinase-2; periapical lesions; symptomatic

1 **Introduction**

2 Apical periodontitis is an inflammatory disorder of periradicular tissues caused
3 by persistent microbial infection within the root canal system of the affected tooth.¹
4 The apical periodontitis can be an acute or chronic stage. The acute inflammation
5 (symptomatic) is an exudative response, whereas chronic inflammation is more
6 proliferative (asymptomatic).²

7 Matrix metalloproteinases (MMPs) are an important family of metal-dependent
8 endopeptidases that represent the major class of enzymes responsible for
9 degradation of extracellular matrix (ECM) components.³ MMP-1 has been implicated
10 as a key in the initiation of the bone resorptive phase of apical periodontitis.⁴ In
11 addition MMP-2, MMP-3, MMP-8, MMP-9 and MMP-13 have been described in
12 periapical periodontitis^{5,6,7,8,9} and plays an important role during periapical pathology
13 development.^{8,10} However, it has been recently suggested that there is good
14 evidence to suspect a significant role of gram-negative bacteria and MMP-9 in
15 symptomatic periapical lesions.¹¹

16 MMP-2 also known as gelatinase A, is a membrane-bound protein that is
17 important for extracellular matrix turnover, preferentially cleaving collagen types IV, V,
18 VII and XI and gelatina.¹² Immunoreactivity to MMP-2 in the periapical lesion was
19 mainly expressed by fibroblasts, keratinocytes, endothelial cells,
20 monocytes/macrophages and osteoblasts.⁵ During the phase of the lesion
21 development, MMP-2 and MMP-9 have been described that can play a critical role.¹⁰
22 On the other hand, it has been reported that MMP-9 levels increased, whereas MMP-
23 2 levels decreased in inflamed pulps compared with healthy pulps.¹³ Moreover, it also
24 been reported different levels between MMP-2 and MMP-9 in acute and chronic
25 periapical abscesses.¹⁴

26 The aim of this study was to test the hypothesis that the expression of MMP-2
27 is significantly elevated in patients with symptomatic apical periodontitis and to
28 correlate this to the detected amount of gram-negative bacteria.

1 **Material and Methods**

2 Patient Selection

3 Twenty patients, with noncontributory medical histories and diagnosed with
4 periapical lesions were selected for this study. The diagnosis of apical periodontitis
5 was based mainly on radiographic examination, demonstrating clear bone loss and
6 disappearance of the periodontal ligament space in the periapical region. All tissue
7 samples ($n=20$) were from upper anterior area involving one tooth only of each
8 patient. The age of the patients ranged from 19 to 41 years old. Only medically free
9 patients were included in this research. All procedures were performed after
10 obtaining proper institutional review board approval based on the regulations of the
11 Ethical Commiteee of the Pontifical Catholic University of Parana, Brazil, and patients
12 signed an informed consent form. The patients were divided into two groups: the
13 symptomatic (SYM) group, which included 10 patients complaining from severe pain
14 and fullness before endodontic surgery, and the asymptomatic (ASYM) group, which
15 included 10 patients with no pain or symptoms.

16 All teeth had been endodontically retreated at least two years before the
17 periapical surgery. In the ASYM group, the image of the periapical lesions had
18 increased when it compared with the initial radiographic of endodontics retreatment.
19 In the SYM group the acute periodontitis was present and it could suggest failure in
20 the retreatment.

21 The periapical surgery was performed in all teeth and the periapical tissue
22 were collected and immediately immersed in 10% neutral buffered formalina for 24
23 hours and then serially cut into 4- μ m sections. At least two sections were processed
24 for immunohistochemical examination. Other sections were processed for histologic
25 examination using gram-negative stain.¹¹

26 Immunohistochemistry

27 The tissue sections on glass slide were deparaffinized by heating at 60 °C,
28 followed by passages through xylene and alcohol grades, and ultimately to water.
29 Antigen retrieval was performed by boiling the slides in 10 MN citrate buffer, pH 6.0

for 10 minutes (min), followed by cooling in the same buffer for 30 min. The endogenous peroxidase was quenched by incubating slides with 0.3% H₂O₂ in methanol for 15 min. Soon afterwards, the sections were incubated in 3% normal serum diluted in distilled water at room temperature for 20 min, and were sequentially incubated with MMP-2 (37150, Abcam, USA). Following the incubation period, (overnight), the sections were washed with PBS and incubated with AdvanceTM HRP Enzyme (DAKO®, USA). The sections were washed with TBS tris pH 7.3. The sections were treated with substrate 3, 3'-diaminobenzidine tetrahydrochloride (DAB) (Sigma Aldrich, D5637, St. Louis, MO, USA) for up to 5 min at room temperature. DAB was rinsed. Afterward, counterstaining with Mayer hematoxylin and cover slipping were performed as the final steps before slides were examined under a light microscope.

Gram Stain

After deparaffinization and rehydration, sections were stained in 1% Crystal violet for 15 minutes. Sections were then flooded for 30 seconds with lugol iodine by acetone for 2 seconds. The sections were washed immediately after with water and counterstained with carbolfuchsin for 20 seconds and then washed with water and blotted dry. Gram-negative bacteria were stained pink-red.¹¹

Quantitative Image Analysis

For each positive section, 10 microscopic fields showing the highest immunopositivity were selected and photomicrographed at a magnification of 400X (BX50; Olympus, Tokyo, Japan). All steps for immunohistochemical and gram stain analysis were performed using image analysis software (Dino-eye, Anmo electronics corporation, Taiwan). For MMP-2, the area fraction of the positive cells was measured, and the percentage of the MMP-2- immunopositive area to the total area of the microscope field was calculated. For gram-negative-stained cells, the number of cells showing the pink-red color was counted per microscopic field.¹¹

1 Statistical Analysis

2 Data were explored for normality using Kolmogorov-Smirnov and Shapiro-Wilk
3 tests. The tests showed that data are normally distributed (parametric). The Student's
4 test was used to compare the SYM and ASYM groups. The Pearson correlation
5 coefficient was used to determine a significant correlation between the number of
6 cells and the MMP-2 level.¹¹ The significance level was set at $p \leq .05$. Statistical
7 analysis was performed.

8 Results

9 For the MMP-2 immunopositive area percent, the ASYM group showed a
10 statistically significant higher mean area percent than the SYM group ($p = .027$, Figure
11 1). For gram-negative cells, the SYM group showed a statistically significantly higher
12 mean number than the ASYM group ($p = .003$, Figure 2).




Figura 1 – Quantidade de bactérias Gram-Negativa




Figura 2 – Expressão de MMP-2

14
15 Immunohistochemically, MMP-2 was expressed mainly by macrophage-like
16 cells, fibroblast-like cells, epithelial cells, and endothelial cells (Figure 3). There was
17 not a statistically significant positive correlation between number of gram-negative
18 cells and the MMP-2 area percent ($p = .187$).




Figura 3 - A: Grupo Assintomático – Área com células inflamatórias imunopositivas para MMP-2, na seta sugestivo de macrófago. B: Grupo Sintomático - Área com células inflamatórias imunopositivas para MMP-2, na seta sugestivo de neutrófilo. C: Grupo Assintomático – Área com células imunopositivas para MMP-2. D: Grupo Assintomático – Área com células imunopositivas para MMP

Discussion

MMPs have been identified in both pulpal and periapical inflammation.^{13,6} However, MMP family members are involved in normal physiology and in pathological events that occur in the oral environment.¹⁵

MMPs play an important role in dental pulp tissue destruction and it has been proposed that MMP-1, MMP-8, MMP-9 and MMP-13 together are involved in jaw cyst expansion.^{7,8,16}

1 Previous studies have shown immunostaining for MMP-2^{5,10} In the present
2 study, positive MMP-2 staining was detected in the macrophage-like cells, fibroblast-
3 like cells, , epithelial cells, and endotelial cells.

4 Increased levels of MMP-2 in human pulp and periodontal ligament all cultures
5 has been associated with porphyromonas endodontalis and gingivalis (black-
6 pigmented bacteroides), which may cause severe periapical abscesses.¹⁷ On the
7 other hand, MMP-2 could be detected in acute apical abscess samples at lower
8 levels than MMP-9.¹⁴ Differents patterns of expression between gelatinases MMP-2
9 and MMP-9 have been described. Human pulp cells culture have been
10 demonstreded to produce primarily MMP-2 and MMP-9. When IL-1 was introduced,
11 the cells have elevated levels of MMP-2, however IL-1 did not affect MMP-9 level
12 during the 8-day culture period.¹⁷

13 The most original findings of this investigation is the pattern of expression of
14 MMP-2 which was the opposite of a recent study using the same methodology, but
15 with MMP-9.¹⁰ MMP-2 and MMP-9 have been described how an importante role
16 during the phase of the periapical lesion development. On the other hand, when the
17 periapical lesion is established, the gelatinases may have a different behavior. In this
18 study, MMP-2 immunostaining in ASYM was higher when compared to the SYM
19 group, however, it may suggest a different role when compared to the MMP-9 in
20 acute periodontitis.

21 It has been suggested that some gram-negative bacteria are involved with
22 symptomatic lesions.¹⁸ However the presente study did not show a correlation
23 between the gram-negative bacteria and an increase in MMP-2 activity in
24 symptomatic periapical lesions. It can be suggested the balance between
25 gelatinases, probably there are different patterns, when the MMP-9 increases the
26 MMP-2 receives signals to decrease.

27 For gram-negative bacterias, the SYM group showed a statistically
28 significantly higher mean number than the ASYM group. Based on the results, it can
29 be concluded that gram-negative bacteria may not play an important role in MMP-2
30 activity when the periapical lesion is symptomatic.

References

1. Kakehashi S, Stanley HR, Fitzgerald RJ. The effects of surgical exposures of dental pulps in germ-free and conventional laboratory rats. *Oral surg Oral Med Oral Pathol Oral Radiol Endod* 1965;20:340-9.
2. Marton IJ, Kiss C. Protective and destructive immune reactions in apical periodontitis. *Oral Microbiol Immunol* 2000;15:139-50.
3. Birkedal-Hansen H, Moore WG, Bodden MK et al. Matrix metalloproteinases: a review. *Crit Rev Oral Biol Med* 1993;4:197-250.
4. Lin SK, Kok SH, Kuo MYP, et al. Sequential expression of MMP-1, TIMP-1, IL-6 and COX-2 genes in induced periapical lesions in rats. *Eur J Oral Sci* 2002;110:246-53.
5. Shin SJ, Lee J, Baek SH, Lin SS. Tissue levels of matrix metalloproteinase in pulps and periapical lesions. *J Endod* 2002;28:313-5.
6. Wahlgren J, Salo T, Teronen O, Luoto H, Sorsa T, Tjäderhane L. Matrix metalloproteinase-8 (MMP-8) in pulpal and periapical inflammation and periapical root-canal exsudates. *Int Endod J* 2002;35:897-904.
7. Leonardi R, Caltabiano R, Loreto C. Collagenase-3 (MMP-13) is expressed in periapical lesions: an immunohistochemical study. *Int Endod J* 2005;38:297-301.
8. Carneiro E, Menezes R, Garlet GP, et al. Expression analysis of matrix metalloproteinase-9 in epithelialized and non-epithelialized apical periodontitis lesions. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2009;107:127-32.
9. Paula-Silva FWG, D'Silva NJ, Silva LAB, Kapila YL. High matrix metalloproteinase activity is a hallmark of periapical granulomas. *J Endod* 2009;35:723-6.
10. Corotti MV, Zambuzzi WF, Paiva KB, et al. Immunolocalization of matrix metalloproteinases-2 and -9 during apical periodontitis development. *Arch Oral Biol* 2009;54:764-71.
11. Ahmed GM, El-Baz AA, Hashem AAR, Shalaan AK. Expression levels of matrix metalloproteinase-9 and gram-negative bacteria in symptomatic and asymptomatic periapical lesions. *J Endod* 2013 Apr;39(4):444-8. doi: 10.1016/j.joen.2012.11.009. Epub 2013 Jan 16.

- 1
- 2 12. Price SJ, Greaves DR, Watkins H. Identification of novel functional genetic
- 3 variants in the human matrix metalloproteinase-2 gene:role of Sp1 in allele-specific
- 4 transcriptional regulation. *J Biol chem* 2001;27:7549-58.
- 5 13. Gusman H, Santana RB, Zehnder M. Matrix metalloproteinase levels and
- 6 gelatinolytic activity in clinically healthy and inflamed human dental pulps. *Eur J Oral*
- 7 *Sci* 2002;110:353-7.
- 8 14. Buzoglu HD, Unal H, Ulger C, et al. The zymographic evaluation of
- 9 gelatinase (MMP-2 and -9) levels in acute and chronic periapical abscesses. *Oral*
- 10 *Surg Oral Med Oral Pathol Oral Radiol Endod* 2009;108:e-121-26.
- 11 15. Hannas AR, Pereira JC, Granjeiro JM, Tjaderhane L. The role of matrix
- 12 metalloproteinases in the oral environment. *Acta Odont Scand* 2007;65:1-13.
- 13 16. Teronen O, Salo T, Konttinen YT, et al. Identification and characterization
- 14 of gelatinase/type IV collagenase in jaw cysts. *J Oral Pathol Med* 1995;24:78-84.
- 15 17. Chang YC, Lai CC, Yang SF, Chan Y, Hsieh YS. Stimulation of matrix
- 16 metalloproteinases by black-pigmented bacteroides in human pulp and periodontal
- 17 ligament cell cultures. *J Endod* 2002;28:90-3.
- 18 18. Siqueira JF. Update on endodontic microbiology: candidate pathogens and
- 19 patterns of colonization. *Endod Pract today* 2009;2:7-20.
- 20
- 21

1

2

3

4

5

6

7

ANEXOS

8

1

2

3

4

5

6

7

Parecer do Comitê de Ética

8

9

10

11

12

13

14

15

16

17



Comitê de Ética
em Pesquisa da
PUCPR



ASSOCIAÇÃO PARANAENSE DE CULTURA - PUCPR

PARECER CONSUBSTANCIADO DO CEP

DADOS DO PROJETO DE PESQUISA Título da Pesquisa: EXPRESSÃO
DE MA TRIZ MET ALOPROTEASE EM LESÕES PERIAPICAIS

SINTOMÁTICAS E ASSINTOMÁTICAS **Pesquisador:** Everdan Carneiro

Área Temática: Versão: 1 **CAAE:** 24267613.5.0000.0020 **Instituição**

Proponente: Pontifícia Universidade Católica do Parana - PUCPR

Patrocinador Principal: Financiamento Próprio

DADOS DO PARECER Número do Parecer: 459.509

Data da Relatoria: 13/11/2013

Apresentação do Projeto:

A infecção bacteriana na polpa dentária induz uma resposta inflamatória, que, não sendo tratada, determina a sua destruição e consequente contaminação do sistema de canais radiculares e túbulos dentinários, desencadeando, por sua vez, infecção no periodonto apical. A persistência desse evento provoca a migração, ativação e a interação coordenada de células imuno-competentes, caracterizando a periodontite apical. A degradação de proteínas da matriz extracelular pelas metaloproteases da matriz (MMPs) ocorre nos processos fisiológicos (turnover) bem como

nos processos patológicos (inflamação, neoplasias, etc).

Objetivo da Pesquisa:

Objetivo Primário: Avaliar a expressão de MMP-2 em lesões periapicais, granulomas e cistos periapicais, verificando as células envolvidas para MMP-2 por meio de marcações de imuno-histoquímica.

Objetivo Secundário: Verificar os níveis de expressão de MMP-2 em lesões

- 1 periapicais sintomáticas e assintomáticas.
- 2 **Avaliação dos Riscos e Benefícios:**
- 3 Riscos: Não existem riscos envolvidos. O material encontra-se embocado no
- 4 Serviço de Patologia e faz parte da rotina desse Serviço a análise
- 5 microscópica desse tecido coletado na clínica para fins diagnósticos.
- 6 Benefícios: Os benefícios para o participante da pesquisa é que existirá além
- 7 do exame anatomopatológico de rotina, um exame imunohistoquímico, sem
- 8 riscos e necessidade de outras coletas.
- 9 **Comentários e Considerações sobre a Pesquisa:**
- 10 Um total de 20 amostras de tecidos retirados de cirurgias paraendodônticas,
- 11 realizadas pelo Serviço de Endodontia da PUCPR, serão coletadas
- 12 encaminhadas ao Serviço de Patologia para análise e laudo de
- 13 anatomopatológico. Os resultados serão comparados conforme protocolo
- 14 estabelecido no projeto de pesquisa e analisados estatisticamente.
- 15 **Considerações sobre os Termos de apresentação obrigatória:**
- 16 O TCLE está presente e escrito de maneira adequada. Sugere-se que o
- 17 pesquisador acrescente a seguinte frase no termo: "Em caso de reclamação
- 18 ou qualquer tipo de denúncia sobre este estudo devo ligar para o CEP
- 19 PUCPR (41) 3271-2292 ou mandar um email para nep@pucpr.br."
- 20 **Recomendações:**
- 21 Seguir recomendação de adequação do TCLE.
- 22 **Conclusões ou Pendências e Lista de Inadequações:**
- 23 O presente projeto de pesquisa está aprovado no quesito ético.
- 24 **Situação do Parecer:**
- 25 Aprovado
- 26 **Necessita apreciação da CONEP:**
- 27 Não
- 28 **Considerações Finais a critério do CEP:**
- 29 Lembramos aos senhores pesquisadores que, no cumprimento da Resolução
- 30 466/2012, o Comitê de Ética em Pesquisa (CEP) deverá receber relatórios
- 31 anuais sobre o andamento do estudo, bem como a qualquer tempo e a critério
- 32 do pesquisador nos casos de relevância, além do envio dos relatos de

1 eventos adversos, para conhecimento deste Comitê. Salientamos ainda, a
2 necessidade de relatório completo ao final do estudo.

3 Eventuais modificações ou ementas ao protocolo devem ser apresentadas ao
4 CEP-PUCPR de forma clara e sucinta, identificando a parte do protocolo a ser
5 modificado e as suas justificativas.

6 Se a pesquisa, ou parte dela for realizada em outras instituições, cabe ao
7 pesquisador não iniciá-la antes de receber a autorização formal para a sua
8 realização. O documento que autoriza o início da pesquisa deve ser
9 carimbado e assinado pelo responsável da instituição e deve ser mantido em
10 poder do pesquisador responsável, podendo ser requerido por este CEP em
11 qualquer tempo.

12 CURITIBA, 18 de Novembro de 2013

13 **Assinador por:**

14 **NAIM AKEL FILHO (Coordenador)**

15 _____
16 **Endereço:** Rua Imaculada Conceição 1155 **Bairro:** Prado Velho **CEP:** 80.215-901
17 **UF:** PR **Município:** CURITIBA **Telefone:** (41)3271-2292 **Fax:** (41)3271-2292 **E-**
18 **mail:** nep@pucpr.br

1

2

3

4

5

6

7

Análise Estatística

8

9

1 Resultados

Testes de Normalidade

Grupo		Kolmogorov-Smirnov ^a			Shapiro-Wilk		
		Estatística	df	Valor p	Estatística	df	Valor p
Expressão de MMP-2 (µ2)	Sintomático	,159	10	,200 [*]	,965	10	,844
	Assintomático	,256	10	,062	,850	10	,059
Quantidade de Bactérias Gram-Negativa	Sintomático	,152	10	,200 [*]	,914	10	,306
	Assintomático	,180	10	,200 [*]	,904	10	,242

*. Este é um limite inferior da significância verdadeira.

a. Correlação de Significância de Lilliefors

Descritivos

		N	Média	Desvio Padrão	Erro Padrão	média		Mínimo	Máximo
						Limite inferior	Limite superior		
Expressão de MMP-2 (µ2)	Sintomático	10	0,17	0,12	0,04	0,09	0,25	0,01	0,37
	Assintomático	10	0,67	0,71	0,23	0,16	1,18	0,02	2,21
	Total	20	0,42	0,56	0,13	0,16	0,68	0,01	2,21
Quantidade de Bactérias Gram-Negativa	Sintomático	10	10,52	4,40	1,39	7,38	13,66	6,00	19,20
	Assintomático	10	5,70	1,87	0,59	4,36	7,04	3,00	8,00
	Total	20	8,11	4,11	0,92	6,18	10,04	3,00	19,20

Teste de Homogeneidade de Variâncias

	Estatística de Levene	df1	df2	Valor p
Expressão de MMP-2 (µ2)	13,884	1	18	0,0015
Quantidade de Bactérias Gram-Negativa	6,034	1	18	0,0244


Teste de amostras independentes

		teste-t para igualdade de Médias								Potência observada ⁽¹⁾
		t	df	Valor p (bilateral)	Valor p (unilateral)	Diferença média	Erro padrão de diferença	95% Intervalo de Confiança da Diferença		
								Inferior	Superior	
Expressão de MMP-2 (µ2)	Variâncias iguais não assumidas	-2,1832	9,4715	0,0554	0,0277	-0,4995	0,2288	-1,0132	0,0142	0,5423
Quantidade de Bactérias Gram-Negativa	Variâncias iguais não assumidas	3,1895	12,1657	0,0077	0,0038	4,8200	1,5112	1,5323	8,1077	0,8544


(1). Calculado usando alfa = ,05

Valor p < 0,05 (teste unilateral) indica diferença estatisticamente significante entre os dois grupos


1



2



3



CORRELAÇÃO GERAL

Correlações		Expressão de MMP-2 (μ 2)	Quantidade de Bactérias Gram-Negativa
Expressão de MMP-2 (μ 2)	Correlação de Pearson	1	-,308
	Valor p		,187
	N	20	20
Quantidade de Bactérias Gram-Negativa	Correlação de Pearson	-,308	1
	Valor p	,187	
	N	20	20

CORRELAÇÃO DENTRO DO GRUPO SINTOMÁTICO

Correlações		Expressão de MMP-2 (μ 2)	Quantidade de Bactérias Gram-Negativa
Expressão de MMP-2 (μ 2)	Correlação de Pearson	1	-,014
	Valor p		,969
	N	10	10
Quantidade de Bactérias Gram-Negativa	Correlação de Pearson	-,014	1
	Valor p	,969	
	N	10	10

CORRELAÇÃO DENTRO DO GRUPO 2

Correlações		Expressão de MMP-2 (μ 2)	Quantidade de Bactérias Gram-Negativa
Expressão de MMP-2 (μ 2)	Correlação de Pearson	1	-,115
	Valor p		,753
	N	10	10
Quantidade de Bactérias Gram-Negativa	Correlação de Pearson	-,115	1
	Valor p	,753	
	N	10	10

1 GRAM

Número da lâmina	Área de GRAM	Grupo
2011012-1	3	2
2011012-2	8	2
2011012-3	9	2
2011012-4	7	2
2011012-5	3	2
2011012-6	7	2
2011012-7	3	2
2011012-8	9	2
2011012-9	6	2
2011012-10	5	2
2011012-média	6	2

2

Número da lâmina	Área de GRAM	Grupo
2013038-1	7	2
2013038-2	4	2
2013038-3	6	2
2013038-4	10	2
2013038-5	9	2
2013038-6	9	2
2013038-7	6	2
2013038-8	5	2
2013038-9	3	2
2013038-10	7	2
2013038-média	6,6	2

3

Número da lâmina	Área de GRAM	Grupo
2012025-1	8	2
2012025-2	6	2
2012025-3	5	2
2012025-4	8	2
2012025-5	7	2
2012025-6	10	2
2012025-7	8	2
2012025-8	11	2
2012025-9	7	2
2012025-10	11	2
2012025-média	8,1	2

4

Número da lâmina	Área de GRAM	Grupo
2013013-1	5	2
2013013-2	2	2
2013013-3	1	2
2013013-4	2	2
2013013-5	4	2
2013013-6	2	2
2013013-7	2	2
2013013-8	3	2
2013013-9	1	2
2013013-10	3	2
2013013-média	2,5	2

1

Número da lâmina	Área de GRAM	Grupo
2013047-1	9	2
2013047-2	8	2
2013047-3	13	2
2013047-4	4	2
2013047-5	11	2
2013047-6	7	2
2013047-7	8	2
2013047-8	4	2
2013047-9	7	2
2013047-10	5	2
2013047-média	7,6	2

2

Número da lâmina	Área de GRAM	Grupo
2013050-1	2	2
2013050-2	6	2
2013050-3	9	2
2013050-4	2	2
2013050-5	4	2
2013050-6	8	2
2013050-7	6	2
2013050-8	2	2
2013050-9	4	2
2013050-10	5	2
2013050-média	4,8	2

3

4

5

Número da lâmina	Área de GRAM	Grupo
2013069-1	3	2
2013069-2	5	2
2013069-3	3	2
2013069-4	6	2
2013069-5	3	2
2013069-6	2	2
2013069-7	4	2
2013069-8	4	2
2013069-9	2	2
2013069-10	3	2
2013069-média	4	2

1

Número da lâmina	Área de GRAM	Grupo
2013072-1	3	2
2013072-2	3	2
2013072-3	7	2
2013072-4	5	2
2013072-5	3	2
2013072-6	5	2
2013072-7	4	2
2013072-8	2	2
2013072-9	1	2
2013072-10	2	2
2013072-média	4	2

2

Número da lâmina	Área de GRAM	Grupo
2013073-1	10	2
2013073-2	12	2
2013073-3	7	2
2013073-4	6	2
2013073-5	8	2
2013073-6	5	2
2013073-7	7	2
2013073-8	3	2
2013073-9	4	2
2013073-10	11	2
2013073-média	7,3	2

3

4

5

Número da lâmina	Área de GRAM	Grupo
2013048-1	8	2
2013048-2	8	2
2013048-3	10	2
2013048-4	7	2
2013048-5	6	2
2013048-6	2	2
2013048-7	7	2
2013048-8	4	2
2013048-9	4	2
2013048-10	3	2
2013048-média	5,9	2

1

2 MMP

Número da lâmina	Área da MMP-2 (micrômetros quadrados)	Grupo
2011012-1	0,44292092	2
2011012-2	0,10522959	2
2011012-3	0,61766583	2
2011012-4	0,2002551	2
2011012-5	0,33003825	2
2011012-6	0,12308674	2
2011012-7	0,12308675	2
2011012-8	0,12308676	2
2011012-9	0,12308677	2
2011012-10	0,12308678	2
2011012-média	0,231154349	2

3

Número da lâmina	Área da MMP-2 (micrômetros quadrados)	Grupo
2013038-1	2,2228954	2
2013038-2	7,561862	2
2013038-3	2,7101402	2
2013038-4	5,5318875	2
2013038-5	6,5443239	2
2013038-6	6,6036353	2
2013038-7	3,2410715	2
2013038-8	5,3017978	2
2013038-9	2,9639668	2
2013038-10	3,6801658	2
2013038-média	4,63617462	2

4

Número da lâmina	Área da MMP-2 (micrômetros quadrados)	Grupo
2012025-1	0,20567602	2
2012025-2	0,14604591	2
2012025-3	0,04432397	2
2012025-4	0,1916454	2
2012025-5	0,19515306	2
2012025-6	0,14987245	2
2012025-7	0,07397959	2
2012025-8	0,24585459	2
2012025-9	0,07684949	2
2012025-10	0,0851403	2
2012025-média	0,141454078	2

1

Número da lâmina	Área da MMP-2 (micrômetros quadrados)	Grupo
2013013-1	0,09534438	2
2013013-2	0,00892857	2
2013013-3	0,02710459	2
2013013-4	0,00510204	2
2013013-5	0,02008928	2
2013013-6	0,03794642	2
2013013-7	0,03858418	2
2013013-8	0,01116071	2
2013013-9	0,00892857	2
2013013-10	0,03156887	2
2013013-média	0,028475761	2

2

Número da lâmina	Área da MMP-2 (micrômetros quadrados)	Grupo
2013047-1	0,10299744	2
2013047-2	0,23309949	2
2013047-3	0,27232143	2
2013047-4	0,04368622	2
2013047-5	0,10044643	2
2013047-6	0,38169643	2
2013047-7	0,47672191	2
2013047-8	0,21301021	2
2013047-9	0,13679847	2
2013047-10	0,10267857	2
2013047-média	0,20634566	2

3

4

Número da lâmina	Área da MMP-2 (micrômetros quadrados)	Grupo
2013050-1	18,083227	2
2013050-2	0,5194515	2
2013050-3	1,9620535	2
2013050-4	23,899553	2
2013050-5	21,390944	2
2013050-6	0,92793363	2
2013050-7	2,7209821	2
2013050-8	2,4661989	2
2013050-9	0,96715558	2
2013050-10	1,6167091	2
2013050-média	7,455420831	2

1

Número da lâmina	Área da MMP-2 (micrômetros quadrados)	Grupo
2013069-1	1,5373087	2
2013069-2	0,39540815	2
2013069-3	1,4681122	2
2013069-4	1,3711735	2
2013069-5	1,5232780	2
2013069-6	0,7225765	2
2013069-7	1,1868622	2
2013069-8	0,45503825	2
2013069-9	0,35140306	2
2013069-10	0,21492347	2
2013069-média	0,922608403	2

2

Número da lâmina	Área da MMP-2 (micrômetros quadrados)	Grupo
2013072-1	0,15146683	2
2013072-2	0,88903058	2
2013072-3	1,7155612	2
2013072-4	0,52168369	2
2013072-5	0,34056121	2
2013072-6	0,19770408	2
2013072-7	0,57621175	2
2013072-8	0,77582908	2
2013072-9	2,3281250	2
2013072-10	0,88488519	2
2013072-média	0,838105861	2

3

4

Número da lâmina	Área da MMP-2 (micrômetros quadrados)	Grupo
2013073-1	0,44897959	2
2013073-2	1,2975128	2
2013073-3	1,3013393	2
2013073-4	2,327806	2
2013073-5	0,79464287	2
2013073-6	1,5121173	2
2013073-7	1,5440050	2
2013073-8	1,3121811	2
2013073-9	1,7975128	2
2013073-10	0,36096939	2
2013073-média	1,269706615	2

1

Número da lâmina	Área da MMP-2 (micrômetros quadrados)	Grupo
2013048-1	0,05293367	2
2013048-2	0,0041454	2
2013048-3	0,01307397	2
2013048-4	0,01690051	2
2013048-5	0,11575255	2
2013048-6	0,07908163	2
2013048-7	0,08067601	2
2013048-8	0,14285713	2
2013048-9	0,01849489	2
2013048-10	0,12978315	2
2013048-média	0,065369891	2

2
3
4
5
6
7
8

Legenda:

Grupo 1- sintomático

Grupo 2- assintomático

1 Resultados Finais

ExpressãodeMMP2 μ 2	QuantidadedeBactériasGramNegativa	Grupo
0,26	19,20	1
0,09	13,00	1
0,18	15,00	1
0,37	6,00	1
0,01	6,00	1
0,18	6,00	1
0,31	8,00	1
0,13	12,00	1
0,03	11,00	1
0,14	9,00	1
0,12	6,00	2
1,02	7,00	2
0,15	8,00	2
0,02	3,00	2
0,17	8,00	2
2,21	5,00	2
0,95	3,50	2
0,68	3,50	2
1,31	7,00	2
0,07	6,00	2

2

1

2

3

4

5

6

7

Normas para Publicação

8

9

International Journal of Endodont

The *Journal of Endodontics* is owned by the American Association of Endodontists. Submitted manuscripts must pertain to endodontics and may be original research (eg, clinical trials, basic science related to the biological aspects of endodontics, basic science related to endodontic techniques, case reports, or review articles related to the scientific or applied aspects of endodontics). Clinical studies using CONSORT methods (<http://www.consort-statement.org/consort-statement/>) or systematic reviews using meta-analyses are particularly encouraged. Authors of potential review articles are encouraged to first contact the Editor during their preliminary development via e-mail at JEndodontics@UTHSCSA.edu. Manuscripts submitted for publication must be submitted solely to *JOE*. They must not be submitted for consideration elsewhere or be published elsewhere.

Disclaimer

The statements, opinions, and advertisements in the *Journal of Endodontics* are solely those of the individual authors, contributors, editors, or advertisers, as indicated. Those statements, opinions, and advertisements do not affect any endorsement by the American Association of Endodontists or its agents, authors, contributors, editors, or advertisers, or the publisher. Unless otherwise specified, the American Association of Endodontists and the publisher disclaim any and all responsibility or liability for such materia

Ethics in publishing

For information on Ethics in publishing and Ethical guidelines for journal publication see <http://www.elsevier.com/publishingethics> and <http://www.elsevier.com/journal-authors/ethics>.

Human and animal rights

If the work involves the use of animal or human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans <http://www.wma.net/en/30publications/10policies/b3/index.html>; EU Directive 2010/63/EU for animal experiments http://ec.europa.eu/environment/chemicals/lab_animals/legislation_en.htm; Uniform Requirements for manuscripts submitted to Biomedical journals <http://www.icmje.org>. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

Conflict of interest

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. See also <http://www.elsevier.com/conflictsofinterest>. Further information and an example of a Conflict of Interest form can be found at: http://help.elsevier.com/app/answers/detail/a_id/286/p/7923.

Submission declaration and verification

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see <http://www.elsevier.com/postingpolicy>), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service CrossCheck <http://www.elsevier.com/editors/plagdetect>.

Changes to authorship

This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts:

Before the accepted manuscript is published in an online issue: Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed.

After the accepted manuscript is published in an online issue: Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.

Reporting clinical trials

Randomized controlled trials should be presented according to the CONSORT guidelines. At manuscript submission, authors must provide the CONSORT checklist accompanied by a flow diagram that illustrates the progress of patients through the trial, including recruitment, enrollment, randomization, withdrawal and completion, and a detailed description of the randomization procedure. The CONSORT checklist and template flow diagram can be found on <http://www.consort-statement.org>.

Copyright

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (for more information on this and copyright see <http://www.elsevier.com/copyright>). Acceptance of the agreement will ensure the widest possible dissemination of information. An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal

Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations (please consult <http://www.elsevier.com/permissions>). If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult <http://www.elsevier.com/permissions>.

Retained author rights

As an author you (or your employer or institution) retain certain rights; for details you are referred to: <http://www.elsevier.com/authorsrights>.

Role of the funding source

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

Funding body agreements and policies

Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit <http://www.elsevier.com/fundingbodies>.

Language (usage and editing services)

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's WebShop (<http://webshop.elsevier.com/languageediting/>) or visit our customer support site (<http://support.elsevier.com>) for more information.

Submission

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts source files to a single PDF file of the article, which is used in the peer-review process. Please note that even though manuscript source files are converted to PDF files at submission for the review process, these source files are needed for further processing after acceptance. All correspondence, including notification of the Editor's decision and requests for revision, takes place by e-mail removing the need for a paper trail.

1 *Submit your article*

2 Please submit your article via <http://ees.elsevier.com/joe/>.

3 *General Points on Composition*

4 Authors are strongly encouraged to analyze their final draft with both software (eg,
5 spelling and grammar programs) and colleagues who have expertise in English
6 grammar. References listed at the end of this section provide a more extensive
7 review of rules of English grammar and guidelines for writing a scientific article.

8 Always remember that clarity is the most important feature of scientific writing.
9 Scientific articles must be clear and precise in their content and concise in their
10 delivery because their purpose is to inform the reader. The Editor reserves the right
11 to edit all manuscripts or to reject those manuscripts that lack clarity or precision or
12 that have unacceptable grammar or syntax. The following list represents common
13 errors in manuscripts submitted to the Journal of Endodontics:

14 a. The paragraph is the ideal unit of organization. Paragraphs typically start with an
15 introductory sentence that is followed by sentences that describe additional detail or
16 examples. The last sentence of the paragraph provides conclusions and forms a
17 transition to the next paragraph. Common problems include one-sentence
18 paragraphs, sentences that do not develop the theme of the paragraph (see also
19 section “c,” below), or sentences with little to no transition within a paragraph.

20 b. Keep to the point. The subject of the sentence should support the subject of the
21 paragraph. For example, the introduction of authors’ names in a sentence changes
22 the subject and lengthens the text. In a paragraph on sodium hypochlorite, the
23 sentence, “In 1983, Langeland et al, reported that sodium hypochlorite acts as a
24 lubricating factor during instrumentation and helps to flush debris from the root
25 canals” can be edited to: “Sodium hypochlorite acts as a lubricant during
26 instrumentation and as a vehicle for flushing the generated debris (Langeland et al,
27 1983).” In this example, the paragraph’s subject is sodium hypochlorite and
28 sentences should focus on this subject.

29 c. Sentences are stronger when written in the active voice, that is, the subject
30 performs the action. Passive sentences are identified by the use of passive verbs
31 such as “was,” “were,” “could,” etc. For example: “Dexamethasone was found in this
32 study to be a factor that was associated with reduced inflammation,” can be edited to:
33 “Our results demonstrated that dexamethasone reduced inflammation.” Sentences
34 written in a direct and active voice are generally more powerful and shorter than
35 sentences written in the passive voice.

36 d. Reduce verbiage. Short sentences are easier to understand. The inclusion of
37 unnecessary words is often associated with the use of a passive voice, a lack of
38 focus, or run-on sentences. This is not to imply that all sentences need be short or
39 even the same length. Indeed, variation in sentence structure and length often helps
40 to maintain reader interest. However, make all words count. A more formal way of
41 stating this point is that the use of subordinate clauses adds variety and information
42 when constructing a paragraph. (This section was written deliberately with sentences
43 of varying length to illustrate this point.)

44 e. Use parallel construction to express related ideas. For example, the sentence,
45 “Formerly, endodontics was taught by hand instrumentation, while now rotary

instrumentation is the common method,” can be edited to “Formerly, endodontics was taught using hand instrumentation; now it is commonly taught using rotary instrumentation.” The use of parallel construction in sentences simply means that similar ideas are expressed in similar ways, and this helps the reader recognize that the ideas are related.

f. Keep modifying phrases close to the word that they modify. This is a common problem in complex sentences that may confuse the reader. For example, the statement, “Accordingly, when conclusions are drawn from the results of this study, caution must be used,” can be edited to “Caution must be used when conclusions are drawn from the results of this study.”

g. To summarize these points, effective sentences are clear and precise, and often are short, simple and focused on one key point that supports the paragraph’s theme.

h. Authors should be aware that the JOE uses iThenticate, plagiarism detection software, to ensure originality and integrity of material published in the journal. The use of copied sentences, even when present within quotation marks, is highly discouraged. Instead, the information of the original research should be expressed by the new manuscript author’s own words, and a proper citation given at the end of the sentence. Plagiarism will not be tolerated and manuscripts will be rejected or papers withdrawn after publication based on unethical actions by the authors. In addition, authors may be sanctioned for future publication.

Use of word processing software

It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier: <http://www.elsevier.com/guidepublication>). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

Essential title page information

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.

- **Author names and affiliations.** Where the family name may be ambiguous (e.g., a double name), please indicate this clearly. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.

1 • **Corresponding author.** Clearly indicate who will handle correspondence at all
2 stages of refereeing and publication, also post-publication. **Ensure that phone**
3 **numbers (with country and area code) are provided in addition to the e-mail**
4 **address and the complete postal address. Contact details must be kept up to**
5 **date by the corresponding author.**

6 • **Present/permanent address.** If an author has moved since the work described in
7 the article was done, or was visiting at the time, a 'Present address' (or 'Permanent
8 address') may be indicated as a footnote to that author's name. The address at which
9 the author actually did the work must be retained as the main, affiliation address.
10 Superscript Arabic numerals are used for such footnotes.

11 **Structured abstract**

12 A structured abstract, by means of appropriate headings, should provide the context
13 or background for the research and should state its purpose, basic procedures
14 (selection of study subjects or laboratory animals, observational and analytical
15 methods), main findings (giving specific effect sizes and their statistical significance,
16 if possible), and principal conclusions. It should emphasize new and important
17 aspects of the study or observations.

18 *Abstract Headings*

19 Introduction, Methods, Results, Conclusions

20 **Keywords**

21 Immediately after the abstract, provide a maximum of 6 keywords, using American
22 spelling and avoiding general and plural terms and multiple concepts (avoid, for
23 example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly
24 established in the field may be eligible. These keywords will be used for indexing
25 purposes.

26 **Acknowledgements**

28 Collate acknowledgements in a separate section at the end of the article before the
29 references and do not, therefore, include them on the title page, as a footnote to the
30 title or otherwise. List here those individuals who provided help during the research
31 (e.g., providing language help, writing assistance or proof reading the article, etc.).

32 The authors deny any conflicts of interest related to this study.

33 **Original Research Article Guidelines**

34 *Title Page*

35 The title describes the major emphasis of the paper. It must be as short as possible
36 without loss of clarity. Avoid abbreviations in the title because this may lead to
37 imprecise coding by electronic citation programs such as PubMed (eg, use sodium
38 hypochlorite rather than NaOCl). The author list must conform to published standards
39 on authorship (see authorship criteria in the Uniform Requirements for Manuscripts
40 Submitted to Biomedical Journals at www.icmje.org). Include the manuscript title; the
41 names and affiliations of all authors; and the name, affiliation, and full mailing

address (including e-mail) of the corresponding author. This author will be responsible for proofreading page proofs and ordering reprints when applicable. Also highlight the contribution of each author in the cover letter.

Abstract

The Abstract concisely describes the purpose of the study in 250 or fewer words. It must be organized into sections: Introduction, Methods, Results, and Conclusions. The hypothesis is described in the Abstract Introduction. The Abstract describes the new contributions made by this study. The Abstract word limitation and its wide distribution (eg, PubMed) make it challenging to write clearly. This section is written last by many authors. Write the abstract in past tense because the study has been completed. Provide 3-5 keywords.

Introduction

The introduction briefly reviews the pertinent literature in order to identify the gap in knowledge that the study is intended to address and the limitations of previous studies in the area. Clearly describe the purpose of the study, the tested hypothesis, and its scope. Many successful manuscripts require no more than a few paragraphs to accomplish these goals; therefore, do not perform extensive literature review or discuss the results of the study in this section.

Materials and Methods

The Materials and Methods section is intended to permit other investigators to repeat your experiments. There are 4 components to this section: (1) detailed description of the materials used and their components, (2) experimental design, (3) procedures employed, and (4) statistical tests used to analyze the results. Most manuscripts should cite prior studies that used similar methods and succinctly describe the essential aspects used in the present study. A "methods figure" will be rejected unless the procedure is novel and requires an illustration for comprehension. If the method is novel, then you must carefully describe the method and include validation experiments. If the study used a commercial product, the manuscript must either state that you followed manufacturer's protocol or specify any changes made to the protocol. If the study used an *in vitro* model to simulate a clinical outcome, describe either experiments made to validate the model or previous literature that proved the clinical relevance of the model. The statistical analysis section must describe which tests were used to analyze which dependent measures; *P* values must be specified. Additional details may include randomization scheme, stratification (if any), power analysis as a basis for sample size computation, dropouts from clinical trials, the effects of important confounding variables, and bivariate versus multivariate analysis.

Results

Only experimental results are appropriate in this section; do not include methods, discussion, or conclusions. Include only those data that are critical for the study, as defined by the aim(s). Do not include all available data without justification; any repetitive findings will be rejected from publication. All Figures, Charts, and Tables must be cited in the text in numerical order and include a brief description of the major findings. Consider using Supplemental Figures, Tables, or Video clips that will be published online. Supplemental material often is used to provide additional information or control experiments that support the results section (eg, microarray

data).

Figures

There are 2 general types of figures: type 1 includes photographs, radiographs, or micrographs; type 2 includes graphs. *Type 1*: Include only essential figures and use composite figures containing several panels of photographs, if possible. Each panel must be clearly identified with a letter (eg, A, B, C), and the parts must be defined in the figure legend. A figure that contains many panels counts as 1 figure. *Type 2*: Graphs (ie, line drawings including bar graphs) that plot a dependent measure (on the Y axis) as a function of an independent measure (usually plotted on the X axis). One example is a graph depicting pain scores over time. Use graphs when the overall trend of the results is more important than the exact numeric values of the results. A graph is a convenient way to report that an ibuprofen-treated group reported less pain than a placebo-treated group over the first 24 hours, but pain reported was the same for both groups over the next 96 hours. In this case, the trend of the results is the primary finding; the actual pain scores are not as critical as the relative differences between the NSAID and placebo groups.

Tables

Tables are appropriate when it is critical to present exact numeric values; however, not all results need be placed in either a table or figure. Instead of a simple table, the results could state that there was no inhibition of growth from 0.001%-0.03% NaOCl, and a 100% inhibition of growth from 0.03%-3% NaOCl (N=5/group). If the results are not significant, then it is probably not necessary to include the results in either a table or as a figure.

Acknowledgments

All authors must affirm that they have no financial affiliation (eg, employment, direct payment, stock holdings, retainers, consultantships, patent licensing arrangements, or honoraria), or involvement with any commercial organization with direct financial interest in the subject or materials discussed in this manuscript, nor have any such arrangements existed in the past 3 years. Disclose any potential conflict of interest. Append a paragraph to the manuscript that fully discloses any financial or other interest that poses a conflict. Disclose all sources and attribute all grants, contracts, or donations that funded the study. Specific wording: "The authors deny any conflicts of interest related to this study."

References

The reference style can be learned from reading past issues of *JOE*. References are numbered in order of citation. Place text citation of the reference Arabic number in parentheses at the end of a sentence or at the end of a clause that requires a literature citation. Do not use superscript for references. Original reports are limited to 35 references. There are no limits in the number of references for review articles.

Other Article Types and Guidelines

Manuscripts submitted to *JOE* that are not Original Articles must fall into one of the following categories. Abstract limit: 250 words. Note that word limits, listed by type, do not include figure legends or References. If you are not sure whether your manuscript falls within one of the categories listed or if you would like to request pre-approval to submit additional figures, contact the Editor at JEndodontics@uthscsa.edu.

CONSORT Randomized Clinical Trial

Must strictly adhere to the Consolidated Standards of Reporting Trials—CONSORT—minimum guidelines for publication of randomized clinical trials (<http://www.consort-statement.org>). Word limit: 3500. Headings: Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgments. Maximum number of figures: 4. Maximum number of tables: 4.

Review Article

Either narrative articles or systemic reviews/meta-analyses. Case Report/Clinical Techniques articles, even when they include an extensive review of the literature, are categorized as Case Report/Clinical Techniques. Word limit: 3500. Headings: Abstract, Introduction, Discussion, Acknowledgments. Maximum number of figures: 4. Maximum number of tables: 4.

Clinical Research

Prospective or retrospective studies of patients or patient records, research on biopsies excluding the use of human teeth for technique studies. Word limit: 3500. Headings: Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgments. Maximum number of figures: 4. Maximum number of tables: 4.

Basic Research—Biology

Animal or culture studies of biological research on physiology, development, stem cell differentiation, inflammation, or pathology. Primary focus is on biology. Word limit: 2500. Headings: Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgments. Maximum number of figures: 4. Maximum number of tables: 4.

Basic Research—Technology

Focus primarily on research related to techniques and materials used, or on potential clinical use, in endodontics. Word limit: 2500. Headings: Abstract, Introduction, Material and Methods, Results, Discussion, Acknowledgments. Maximum number of figures: 3. Maximum number of tables: 3.

Case Report/Clinical Techniques

Reports of an unusual clinical case or use of a cutting edge technology in a clinical case. Word limit: 2500. Headings: Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgments. Maximum number of figures: 4. Maximum number of tables: 4.

Units

Follow internationally accepted rules and conventions: use the international system of units (SI). If other units are mentioned, please give their equivalent in SI.

Database linking

Elsevier encourages authors to connect articles with external databases, giving their readers one-click access to relevant databases that help to build a better understanding of the described research. Please refer to relevant database identifiers using the following format in your article: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN). See <http://www.elsevier.com/databaselinking> for more information and a full list of supported databases.

Artwork

Electronic artwork

General points

- Make sure you use uniform lettering and sizing of your original artwork.
- Embed the used fonts if the application provides that option.
- Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Provide captions to illustrations separately.
- Size the illustrations close to the desired dimensions of the printed version.
- Submit each illustration as a separate file.

A detailed guide on electronic artwork is available on our website:

 <http://www.elsevier.com/artworkinstructions>

You are urged to visit this site; some excerpts from the detailed information are given here.

Formats

If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.

Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings, embed all used fonts.

TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.

TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a

minimum of 1000 dpi.

TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

Please do not:

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;

- Supply files that are too low in resolution;

- Submit graphics that are disproportionately large for the content.

Color artwork

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF) or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color on the Web (e.g., ScienceDirect and other sites) in addition to color reproduction in print. For further information on the preparation of electronic artwork, please see <http://www.elsevier.com/artworkinstructions>.

Figure captions

Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Tables

Number tables consecutively in accordance with their appearance in the text. Place footnotes to tables below the table body and indicate them with superscript lowercase letters. Avoid vertical rules. Be sparing in the use of tables and ensure that the data presented in tables do not duplicate results described elsewhere in the article.

References

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not allowed in the reference list, but they may be mentioned in the text. Citation of a reference as "in press" implies that the item has been accepted for publication.

Reference links

Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is encouraged.

Web References

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references are included in the reference list.

References in a special issue

Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

Reference style

Text: Indicate references by Arabic numerals in parentheses, numbered in the order in which they appear in the text. *List:* Number the references in the list in the order in which they appear in the text. List 3 authors then et al.

Examples:

Journal article:

1. Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. *J Sci Commun.* 2010;163:51–59.

Book:

2. Strunk W Jr, White EB. *The Elements of Style*, 4th ed. New York: Longman; 2000.

Chapter in an edited book:

3. Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, Smith RZ, eds. *Introduction to the Electronic Age*. New York: E-Publishing; 2009:281–304.

Journal abbreviations source

Journal names are abbreviated according to Index medicus.

Video data

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a preferred maximum size of 50 MB. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect: <http://www.sciencedirect.com>. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate

image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages at <http://www.elsevier.com/artworkinstructions>. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

AudioSlides

The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. More information and examples are available at <http://www.elsevier.com/audioslides>. Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

Supplementary data

Elsevier accepts electronic supplementary material to support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier Web products, including ScienceDirect: <http://www.sciencedirect.com>. In order to ensure that your submitted material is directly usable, please provide the data in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit our artwork instruction pages at <http://www.elsevier.com/artworkinstructions>.

Submission checklist

The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item.

Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address
- Phone numbers

All necessary files have been uploaded, and contain:

- Keywords
- All figure captions
- All tables (including title, description, footnotes)

Further considerations

- Manuscript has been 'spell-checked' and 'grammar-checked'
- References are in the correct format for this journal
- All references mentioned in the Reference list are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Web)
- Color figures are clearly marked as being intended for color reproduction on the Web (free of charge) and in print, or to be reproduced in color on the Web (free of charge) and in black-and-white in print
- If only color on the Web is required, black-and-white versions of the figures are also supplied for printing purposes

For any further information please visit our customer support site at <http://support.elsevier.com>.

Use of the Digital Object Identifier

The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. Example of a correctly given DOI (in URL format; here an article in the journal *Physics Letters B*):

<http://dx.doi.org/10.1016/j.physletb.2010.09.059>

When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to change.

Proofs

One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author (if we do not have an e-mail address then paper proofs will be sent by post) or, a link will be provided in the e-mail so that authors can download the files themselves. Elsevier now provides authors with PDF proofs which can be annotated; for this you will need to download Adobe Reader version 7 (or higher) available free from <http://get.adobe.com/reader>. Instructions on how to annotate PDF files will accompany the proofs (also given online). The exact system requirements are given at the Adobe site: <http://www.adobe.com/products/reader/tech-specs.html>.

If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return them to the Journal Manager at Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections and any other comments (including replies to the Query Form) on a printout of your proof and return by fax. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the

1 Editor. We will do everything possible to get your article published quickly and
2 accurately – please let us have all your corrections within 48 hours. It is important to
3 ensure that all corrections are sent back to us in one communication: please check
4 carefully before replying, as inclusion of any subsequent corrections cannot be
5 guaranteed. Proofreading is solely your responsibility. Note that Elsevier may
6 proceed with the publication of your article if no response is received.

7 **Offprints**

8 The corresponding author, at no cost, will be provided with a personalized link
9 providing 50 days free access to the final published version of the article on
10 [ScienceDirect](https://www.sciencedirect.com). This link can also be used for sharing via email and social networks.
11 For an extra charge, paper offprints can be ordered via the offprint order form which
12 is sent once the article is accepted for publication. Both corresponding and co-
13 authors may order offprints at any time via Elsevier's WebShop ( <http://webshop.elsevier.com/myarticleservices/offprints>). Authors requiring printed
14 copies of multiple articles may use Elsevier WebShop's 'Create Your Own Book'
15 service to collate multiple articles within a single cover (
16 <http://webshop.elsevier.com/myarticleservices/booklets>).
17